The HERO Consortium is at @HOPArx Annual Conference in New Orleans! Come see us Thursday evening for the Late Breaking Research session as we share our work “Building Real-World Evidence Through the HERO Consortium: A Pharmacist-Led Multicenter Initiative” 🩸💊 #HOPA2026
Multicenter retrospective evaluation of treatment for high risk acute promyelocytic #leukemia:
Comparison of the APML4 and ATRA+ATO+GO in high risk #APL conducted by the @HERO_consortium
Free access: https://t.co/Yhk0lqtBNK #LeuSM@Berninini#HemOnc
What is the best treatment for high-risk APL? Are GO-based regimens better than APML4-style? 🤔
Check out our FIRST major multi-center hematology PharmD pub and find out! 👀 #leusm#apl#HEROconsortium
https://t.co/rWRrvYoAWd
Check out our #HERO consortium poster 4267 TODAY at #ASH23! We compared ATRA+ATO+GO vs ATRA+ATO+Ida in HR APL
🩸In real world, 69% of the GO arm required ida for cytoreduction (so not truly chemo free)
🩸🟰 efficacy
🩸🟰 composite safety, but ⬇️ duration of neutropenia in GO arm